Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry

The Plasma Protein Therapeutics Association (PPTA) supports the draft guidance on responding to FDA Form 483 observations, noting its value in providing clarity to manufacturers. However, they request specific clarifications regarding how manufacturers should handle "discussion items" that are not formal observations, seeking assurance that voluntary remediation of these items will not be treated as an admission of a CGMP violation.

The commenter argues that the draft guidance fails to address specific concerns regarding inspector behavior, the lack of time limits for 483 closeouts and EIRs, and issues with the public release of warning letters. They express frustration that the document does not provide meaningful changes or protections for facilities.